Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smarter pacemaker lead save the Heart's pumping power?

NCT ID NCT07831655

NEW Prevention Sponsor: Germans Trias i Pujol Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers compare two ways to place a pacemaker's ventricular lead in people who need permanent pacing for atrioventricular block. One method, conduction system pacing, targets the heart's natural electrical pathways; the other uses the traditional right ventricular apical position. The trial measures left ventricular ejection fraction and checks for pacing-induced cardiomyopathy at six months to see whether conduction system pacing better preserves the heart's pumping ability.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Conduction system pacing, a pacemaker technique that places the lead on the heart's natural electrical pathways
What this could lead to
If it works, this could give doctors a pacing method that protects the heart's pumping function and lowers the chance of pacing-induced heart muscle weakness.
What could go wrong
The trial is small and follows people for only six months, so it may not show a clear difference or predict long-term outcomes. Placing leads on the conduction system can be technically harder and may not suit every patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

116 people

The number who actually took part.

Started

Nov 2020

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Left ventricular ejection fraction greater than 50% by the Simpson four-chamber method before pacemaker implantation. * Indication for permanent pacemaker implantation due to atrioventricular block. * Anticipated ventricular pacing burden greater than 85%. * At least one of the following high-risk features: structural heart disease or native QRS duration greater than 120 ms. * Structural heart disease was defined as previously diagnosed ischemic heart disease, with or without prior myocardial infarction, and/or at least moderate left-sided valvular stenosis or regurgitation, and/or an aortic or mitral valve prosthesis. * Provision of written informed consent. Exclusion Criteria: * Failure to meet all inclusion criteria. * Refusal or inability to provide written informed consent. * Dementia or significant cognitive impairment. * Underlying systemic disease associated with a life expectancy of less than 1 year.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrioventricular block are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrioventricular block

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrioventricular block Cardiac pacing, artificial Pacing-induced cardiomyopathy

Contacts and locations

Locations

  • Hospital Universitari Germans Trias i Pujol, Department of Cardiology

    Badalona, Barcelona, 08916, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.